Financial Performance - Total revenues for 2025 were $4,858,000, a decrease of 3.1% from $5,045,000 in 2024[4] - Net loss attributable to common stockholders for 2025 was $2,339,000, compared to a loss of $7,038,000 in 2024, representing a 66.8% improvement[4] - The company recognized a gain on the sale of intangible assets of $750,000 in 2025, compared to $4,000,000 in 2024[6] - Net cash used in operating activities was $4,739,000 in 2025, an improvement from $9,627,000 in 2024[6] Expenses and Liabilities - Operating expenses increased to $7,358,000 in 2025, up from $8,693,000 in 2024, primarily due to higher cost of revenues[4] - Total liabilities decreased to $2,406,000 in 2025 from $7,294,000 in 2024, a decline of 67.0%[2] Assets and Cash Position - Cash and cash equivalents decreased to $259,000 at the end of 2025 from $4,242,000 at the end of 2024, a decline of 93.9%[2] - Total assets decreased to $6,546,000 in 2025 from $13,517,000 in 2024, a reduction of 51.6%[2] Credit Loss and Shares - The company reported a credit loss of $4,745,000 in 2025, compared to no credit loss in 2024[4] - The weighted-average number of shares used in per share calculations increased to 1,368,057 in 2025 from 1,363,303 in 2024[4]

Financial Information - Kyverna Therapeutics, Inc. announced preliminary financial information for the year ended December 31, 2025, which is unaudited and subject to adjustments[6]. - The financial information provided is based on the company's current expectations and may be adjusted following year-end closing procedures[6]. Executive Appointment - Christi Shaw was appointed as Executive Chairperson of the Board, effective January 12, 2026[8]. - Ms. Shaw's initial annualized salary is set at $400,000, with additional equity awards including options for 185,000 shares and restricted stock units for 30,000 shares, both vesting over four years[10]. - If a "Change in Control" occurs during Ms. Shaw's employment, she will receive full acceleration of vesting for all unvested equity awards[12]. Corporate Information - The company is classified as an emerging growth company under the Securities Act of 1933[5]. - The press release detailing the corporate update and strategic priorities for 2026 was issued on January 12, 2026[6]. - The company is headquartered in Emeryville, California, with a principal executive office located at 5980 Horton St., Suite 550[2]. - The company trades on The Nasdaq Stock Market under the symbol KYTX[5]. Equity Awards - The performance restricted stock units (PRSUs) will vest upon the company's common stock reaching certain price targets, with a value of $200,000 divided by the per share Fair Market Value at the date of grant[10].

Financial Performance - SpyGlass Pharma successfully completed its Initial Public Offering (IPO) in February 2026, raising approximately $172.5 million[5]. - The company reported a net loss of $12.6 million, or ($5.72) per share, for Q4 2025, compared to a net loss of $8.4 million, or ($4.58) per share, for Q4 2024[15]. - Total assets increased to $115.866 billion as of December 31, 2025, compared to $23.318 billion in 2024[25]. - Current assets rose significantly to $108.768 billion in 2025 from $17.406 billion in 2024[25]. - Cash and cash equivalents reached $96.358 billion, a substantial increase from $16.268 billion in the previous year[25]. - Total liabilities decreased to $10.166 billion in 2025 from $11.246 billion in 2024[25]. - Total stockholders' deficit widened to $(98.837) billion in 2025 from $(60.474) billion in 2024[25]. - Common stock additional paid-in capital increased to $5.893 billion in 2025 from $4.387 billion in 2024[25]. - Accounts payable rose to $2.696 billion in 2025, up from $1.978 billion in 2024[25]. - Payroll-related accruals increased to $2.182 billion in 2025 from $1.282 billion in 2024[25]. - Other current liabilities surged to $3.706 billion in 2025 compared to $672 million in 2024[25]. - The aggregate liquidation preference for redeemable convertible preferred stock increased to $200.878 billion in 2025 from $73.542 billion in 2024[25]. Research and Development - Research and Development expenses increased to $7.7 million for Q4 2025, up from $5.7 million in Q4 2024, driven by the hiring of clinical personnel and the initiation of Phase 3 trials[12]. - The BIM-IOL System demonstrated a 34% and 42% reduction in mean intraocular pressure (IOP) for high and low dose groups, respectively, compared to a 35% reduction in the control group[4]. - 98% of evaluable patients in the 78-mcg dose group and 96% in the 39-mcg dose group were free from all topical IOP-lowering medications 12 months post-surgery[4]. - Phase 3 trials for the BIM-IOL System are ongoing, with full enrollment expected in 2027[5]. - The company anticipates presenting additional Phase 1/2 trial results at a future medical meeting[6]. - The BIM-IOL System showed a favorable safety profile with no serious ocular adverse events reported[6]. - SpyGlass Pharma plans to initiate a first-in-human trial for the Bimatoprost Drug Ring System (BIM-DRS) in the second half of 2026[20].

Membership and Revenue - At-risk membership was approximately 115,000, a decrease of approximately 9% compared to the same quarter prior year[5]. - Total revenue for Q4 2025 was $384.8 million, up from $370.7 million in the prior year quarter, with capitated revenue PMPM improving 9% year-over-year to $1,060[5]. - Full-year 2025 total revenue was $1.46 billion, down from $1.50 billion in the prior year, with capitated revenue PMPM improving 5% year-over-year to $1,026[5]. - For 2026, the company projects at-risk members to be between 107,000 and 117,000, with total revenues expected to range from $1.5 billion to $1.7 billion[7]. - Capitated revenue for the year ended December 31, 2025, was $1.429 billion, down from $1.484 billion in 2024, reflecting a decrease of 3.7%[27]. Financial Performance - Medical margin for Q4 2025 was negative $28.7 million, or negative $83 PMPM, compared to a positive margin of $7.3 million, or $19 PMPM in the prior year quarter[5]. - Adjusted EBITDA loss for Q4 2025 was $76.1 million, compared to a loss of $67.6 million in the same quarter prior year[5]. - The company reported a net loss of $165.7 million in Q4 2025, compared to a net loss of $129.1 million in the fourth quarter of the prior year[5]. - Normalized Adjusted EBITDA loss for full-year 2025 was $149.1 million, a $43.9 million year-over-year improvement compared to $193.0 million in 2024[5]. - The net loss for the year ended December 31, 2025, was $323,086, compared to a net loss of $310,378 in 2024, representing an increase of 4.5%[22]. - Net loss for Q4 2025 was $165.714 million, compared to a loss of $129.148 million in Q4 2024, representing an increase of 28.3% year-over-year[24]. - Adjusted EBITDA loss for Q4 2025 was $76.065 million, compared to a loss of $67.582 million in Q4 2024, indicating a deterioration of 12.3% year-over-year[24]. Operating Expenses - Total operating revenue for the year ended December 31, 2025, was $1,459,080, a decrease of 2.8% from $1,500,455 in 2024[20]. - Total operating expenses for the year ended December 31, 2025, were $1,729,381, a decrease of 5.0% compared to $1,821,113 in 2024[20]. - Total operating expense for Q4 2025 was $538.680 million, compared to $509.189 million in Q4 2024, marking an increase of 5.7% year-over-year[31]. - Adjusted operating expense for the year ended December 31, 2025, was $101.778 million, down from $111.880 million in 2024, representing a decrease of 9.7%[31]. Assets and Liabilities - Cash and restricted cash at the end of the year was $25,807, down from $44,102 at the end of 2024, a decrease of 41.5%[22]. - Total assets decreased to $656,641 as of December 31, 2025, from $783,420 in 2024, a decline of 16.2%[16]. - Total liabilities increased to $796,876 as of December 31, 2025, compared to $633,891 in 2024, an increase of 25.8%[16]. - The company incurred interest expense of $55,034 for the year ended December 31, 2025, compared to $22,173 in 2024, an increase of 148.5%[20]. Future Projections - The company expects Adjusted EBITDA for 2026 to be in the range of negative $20 million to positive $40 million, with a midpoint of $10 million, indicating approximately $170 million in year-over-year improvement[6]. - Medical margin for 2026 is projected to be between $160 million and $200 million, with PMPM ranging from $120 to $150[7]. Claims and Reserves - Medical claims expense for the year ended December 31, 2025, was $1.405 billion, slightly up from $1.398 billion in 2024, showing an increase of 0.5%[27]. - Premium deficiency reserve for Q4 2025 was $55.414 million, up from $37.927 million in Q4 2024, representing a significant increase of 46%[31]. Equity and Compensation - Equity-based compensation for the year ended December 31, 2025, was $5.581 million, slightly down from $5.752 million in 2024, reflecting a decrease of 3%[31].

Alzheimer's Disease Overview - Alzheimer's disease currently affects approximately 7 million people in the U.S. and 55 million worldwide, with projected growth to 13 million by 2050[23]. Clinical Trials and Results - The Phase 1 INTERCEPT-AD clinical trial of sabirnetug enrolled 65 participants, with 62 receiving at least one dose, demonstrating a 10.4% overall rate of ARIA-E[25][26]. - The Phase 2 ALTITUDE-AD trial will evaluate sabirnetug with a total of 542 participants, using the Integrated Alzheimer's Disease Rating Scale at 18 months as the primary outcome measure[35]. - Top-line results for the ALTITUDE-AD trial are expected to be announced in late 2026[34]. - The trial established clinical proof of mechanism for sabirnetug in early AD patients, supporting further clinical development[52]. - The most common treatment-emergent adverse events in the INTERCEPT-AD clinical trial were ARIA-E (10.4%), ARIA-H (8.3%), COVID-19 (6.3%), and hypersensitivity (6.3%)[212]. - The overall rate of ARIA-E was 10.4%, including one case of symptomatic ARIA-E (2.1%)[212]. - Delays in patient enrollment and retention in clinical trials could significantly impact the timing of necessary regulatory approvals[217]. - Throughout 2022, the company experienced delays in clinical site initiation and patient enrollment primarily due to the COVID-19 pandemic[218]. - Increased development costs were incurred in the INTERCEPT-AD clinical trial due to enrollment delays, including costs related to initiating additional trial sites[221]. - The company may face challenges in maintaining patient enrollment in clinical trials, which could affect trial outcomes[222]. Safety and Efficacy - Sabirnetug showed a dose-dependent incidence of ARIA-E: 7% for 10 mg/kg or 25 mg/kg and 21% for 60 mg/kg[26]. - Sabirnetug demonstrated a statistically significant reduction in amyloid plaque load (p=0.01) after 6-12 weeks at doses of 60 mg/kg Q4W and 25 mg/kg Q2W[53]. - Statistically significant improvements in CSF biomarkers p-tau181 (p=0.049) and neurogranin (p=0.037) were observed at the 60 mg/kg Q4W dose compared to placebo[62]. - Sabirnetug's safety profile is favorable compared to other treatments, with a lower incidence of adverse effects observed in clinical studies[93]. - The Phase 1 trial for subcutaneous administration of sabirnetug showed mild adverse events with no significant safety issues identified[27]. Product Development and Regulatory Pathway - The company plans to target an IND for the Enhanced Brain Delivery therapy by mid-2027, following promising preclinical data[27]. - The FDA granted Fast Track designation to ACU193 in October 2022, indicating potential for expedited development[65]. - The FDA review process for biologics includes a 60-day initial review period, with standard applications typically reviewed within 10 months and priority reviews within 6 months[132]. - The company must submit annual reports and safety reports to the FDA during the IND process, ensuring compliance with regulatory requirements[127]. - Clinical trials for biologics are conducted in three phases, with Phase 3 requiring two adequate and well-controlled trials for FDA approval[129]. - The FDA may issue an approval letter for a BLA, allowing commercial marketing of the product, or a Complete Response Letter (CRL) detailing deficiencies in the application[134]. - A product candidate may receive Fast Track designation, allowing for more frequent interactions with the FDA and potential rolling review of the BLA[138]. - Breakthrough Therapy designation may be granted if preliminary evidence shows substantial improvement over existing therapies, involving more intensive FDA interaction[139]. - Priority review designation aims for FDA action on marketing applications within six months, compared to ten months under standard review[140]. - Accelerated approval may be granted for products that provide meaningful therapeutic advantages, requiring post-marketing studies to verify clinical benefits[142]. - Orphan Drug Designation (ODD) can be granted for drugs intended to treat rare diseases, providing seven years of exclusivity upon first FDA approval[146]. - The BPCIA grants 12 years of data exclusivity for reference biological products, with biosimilar applications not allowed until four years post-licensure[151]. - Compliance with FDA regulations is ongoing, including record-keeping and reporting adverse experiences, with potential penalties for non-compliance[147]. - Changes to approved products require prior FDA review and approval, impacting the timeline for new indications or labeling claims[148]. - The FDA may withdraw approval if regulatory compliance is not maintained, leading to potential market withdrawal or product recalls[149]. Financial Overview - The company has incurred net losses of $121.3 million and $102.3 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $446.5 million as of December 31, 2025[181]. - The company has no product candidates approved for commercial sale and has never generated any revenue from product sales, indicating a high level of financial risk[181]. - As of December 31, 2025, the company had $54.0 million in cash and cash equivalents and $62.9 million in marketable securities, which are expected to fund operations into early 2027[185]. - The company anticipates continued losses as it develops sabirnetug and seeks regulatory approvals, with significant commercialization expenses expected if approvals are obtained[182]. - The company may need to raise additional funding sooner than anticipated if expenses increase or if it chooses to expand operations more rapidly than currently planned[185]. Market and Competitive Landscape - The company faces competition from several institutions developing AD therapies, including Biogen and Eisai, which have recently launched their own products[101]. - The need for additional AD treatment options is urgent, highlighting the potential market opportunity for sabirnetug if approved[98]. - The market for sabirnetug will depend on the cost of production, which is currently uncertain and could affect its commercial viability[203]. Collaborations and Licensing - A collaboration with JCR Pharmaceuticals includes potential milestone payments of up to $40 million related to development and up to $515 million related to sales, totaling up to $555 million[27]. - The company entered into a Loan Agreement with K2 HealthVentures LLC, borrowing $30.0 million in November 2023, with an option to borrow an additional $20.0 million[191]. - The Loan Agreement includes restrictive covenants that may limit the company's operational flexibility and ability to pursue beneficial business opportunities[192]. - The Lonza License Agreement includes an upfront fee of 1.0 million Swiss Francs and ongoing royalties based on net sales, with obligations expiring 10 years after the first commercial sales[108]. - The Halozyme License Agreement involves a seven-figure upfront payment and milestone payments tied to development and commercialization events for the subcutaneous formulation of sabirnetug[110]. Intellectual Property and Regulatory Compliance - The company holds an exclusive license from Merck for sabirnetug, which includes one issued U.S. patent and 18 foreign patents, projected to expire in July 2031[116]. - The company is focused on obtaining additional patent protections to enhance commercial success, including methods of use and formulation[117]. - The company relies on confidentiality agreements to protect proprietary information and intellectual property rights essential for its business operations[113]. - The company is subject to extensive regulatory requirements that may impact its product development and approval timelines[122]. Employee and Operational Insights - The company had 61 employees as of March 25, 2026, with 40 engaged in research and development and 21 in general and administrative functions[175]. - The company has good employee relations, which is crucial for retaining and incentivizing personnel through equity incentive plans[174]. - The company is incorporated in Delaware and maintains its principal executive offices in Newton, MA[176].

Financial Performance - Approximately 34.0% of Lands' End's yearly net revenue is generated in the fourth fiscal quarter, indicating significant seasonality in revenue [36]. - In Fiscal 2025, Lands' End's top 10 vendors accounted for approximately 63% of merchandise purchases, highlighting reliance on a limited number of suppliers [45]. - Net revenue from the Europe eCommerce distribution channel represented 6.8% of total net revenue in Fiscal 2025 [296]. - A 10% change in foreign currency exchange rates would result in a net revenue change of approximately $9.0 million for Fiscal 2025 [296]. - Foreign currency translation gains, net, for Fiscal 2025 totaled approximately $0.1 million related to international subsidiaries in the United Kingdom and Germany [296]. Business Strategy - Lands' End expects to enhance shareholder value by retiring its term loan, which will provide greater capacity for strategic capital deployment [28]. - The company plans to strategically incorporate AI technologies to optimize business processes and enhance decision-making [31]. - Lands' End aims to improve inventory efficiency and seasonal sell-through by optimizing product margins and leveraging technology solutions [42]. - The company maintains a strong digital presence and invests significantly in brand development through multi-channel marketing campaigns [50]. Workforce and Operations - Lands' End employs approximately 3,900 employees, with about 47% being part-time, reflecting a flexible workforce model [54]. - Over 95% of Lands' End's business is conducted online, with a focus on leveraging data analytics to drive personalization and improve gross margins [31]. Sustainability and Partnerships - The company is committed to sustainability initiatives, including waste reduction and efficient resource management [47]. - A joint venture with WHP Global is expected to close in the first quarter of 2026, which will hold the intellectual property associated with the Lands' End brand [39]. Financial Risks - Each one percentage point change in interest rates associated with the Term Loan Facility would result in a $2.3 million change in annual cash interest expenses [298]. - Assuming the ABL Facility was fully drawn to a principal amount of $225.0 million, each one percentage point change in interest rates would also result in a $2.3 million change in annual cash interest expenses [298]. - As of January 30, 2026, the company had $9.1 million of cash and cash equivalents denominated in foreign currency, primarily in British pound sterling, euro, and Hong Kong dollar [297].

Company Classification and Market Position - The company is classified as a "smaller reporting company" with a market value of common stock held by non-affiliates below $250 million[51]. - The Company serves a diverse customer base, with one customer accounting for 42.86% of total revenue as of December 31, 2025[104]. - The Company plans to trade on a national exchange to improve access to capital resources and broaden its customer base[96]. Product Development and Innovation - The AGMDC division has released over 125 new MMIC chip technology products since its inception, indicating strong product development[53]. - The company is actively developing a new product line of Open Radio Units for Sub 6GHz, certified to meet all ORAN KPI requirements[56]. - The Massive MIMO, 64T64R ORAN, CAT B Radio Network is expected to become the company's flagship product, providing true 5G speeds and enhanced coverage[75]. - The company offers a new line of low noise amplifiers featuring proprietary MMIC technology, covering frequency ranges from 2.0 to 18 GHz[67]. - The Company is focused on developing innovative, high-performance products to maintain and increase market share[95]. Research and Development - Research and development costs for the years ended December 31, 2025 and 2024 were $2,687,176 and $3,590,695, respectively, reflecting investment in emerging technologies[81]. - The company currently holds four patents and plans to file additional patents to protect its intellectual property[109]. - The company has received three patents from the United States Patent and Trademark Office, enhancing its intellectual property portfolio[80]. Manufacturing and Operations - The company relocated its manufacturing facility to Hauppauge, New York, which more than triples its capacity and allows for further expansion[91]. - The company’s strategy includes leveraging its established supply chain and internal capacity to process small and large orders efficiently[91]. Competition and Market Challenges - The company faces competition from established players with greater resources, emphasizing the need for innovation and cost-effective solutions[88]. - The Company is subject to extensive environmental regulations, which impose significant compliance burdens but has not adversely affected its financial statements[106][107]. Partnerships and Certifications - The Company announced a partnership with NGK Electronic Devices to become their US distributor for RF Microwave products, marking NGK's first distribution agreement with a US partner[93]. - The Company is ISO 9001:2015 and AS9120B certified for the distribution of semiconductor materials, ensuring compliance with various regulations[94]. Financial Overview - Supplier A accounted for 58.28% of materials purchased, with total material costs for fiscal year ended December 31, 2025, amounting to $17,496,944[98]. - As of March 19, 2026, the Company has 46 full-time employees and 1 part-time employee, with potential for additional contract hires[110]. - The Company maintains dynamic websites and has updated its e-commerce dashboard to enhance online sales capabilities[103].

Financial Performance - Net sales for the year ended December 31, 2025, were $118,365, a decrease of $9,768 or 7.6% compared to $128,133 in 2024[130] - The Medical Device segment saw a decrease in net sales of $2,706 or 7.8%, while Medical Imaging increased by $2,507 or 6.7%[133] - Gross profit increased to $18,006 in 2025, with a gross margin percentage of 15.2%, up from 13.1% in 2024[134] - Operating income for 2025 was $975, representing 0.8% of net sales, compared to an operating loss of $195 in 2024[139] - Cash flows provided by operating activities were $2,743 in 2025, compared to cash used of $2,250 in 2024[149] Order Backlog and Inventory - The total order backlog as of December 31, 2025, was $77,343, a 17.4% increase from $65,852 in 2024[131] - As of December 31, 2025, the company recorded a contract asset of $15,184 for unbilled customer net sales included in net sales[155] - The company had an inventory reserve of $1,853 as of December 31, 2025, reflecting evaluations of slow-moving, excess, or obsolete inventory[157] Expenses and Charges - Interest expense increased to $964 in 2025 from $744 in 2024 due to higher borrowings and interest rates[140] - Restructuring charges decreased to $266 in 2025 from $571 in 2024, reflecting cost management efforts[138] - General and administrative expenses decreased by $919 or 7.8% in 2025 due to lower incentive compensation accruals[137] Financing Activities - The company entered into a new Credit and Security Agreement with Associated Bank, providing a revolving credit facility of up to $15.0 million[145] - Net cash used in financing activities in 2025 was $1,867, primarily due to net payments on the line of credit[151] - Cash provided by financing activities in 2024 amounted to $2,765, mainly from net proceeds of $2,849 from the line of credit and $345 from notes payable[151] Tax and Equity - The reserve for uncertain tax positions aggregated $110 as of December 31, 2025, indicating potential challenges from tax authorities[159] - The company concluded that it was more likely than not that it would realize its recorded net deferred tax assets during 2025 and 2024[158] - The company's common stock was trading at a value less than its net equity value as of December 31, 2025, but no long-lived asset impairment was required[156] Estimates and Forward-Looking Statements - The majority of net sales are recognized over time, including goods produced under contract manufacturing agreements[155] - The company evaluates its estimates and assumptions regularly, which could impact financial results if they vary substantially[153] - Forward-looking statements in the annual report are based on assumptions that may prove to be inaccurate, highlighting risks and uncertainties[162]

Revenue Growth - Total service revenue for the third quarter reached $1.75 billion, a 20% increase compared to $1.47 billion in the prior year[125] - Total revenue for the nine months ended February 28, 2026, was $4.91 billion, reflecting an 18% increase from $4.14 billion in the prior year[125] - Management Solutions revenue was $1.35 billion for the third quarter, up 23% from $1.10 billion in the prior year[126] - PEO and Insurance Solutions revenue increased by 9% to $397.5 million for the third quarter, compared to $365.4 million in the prior year[126] - Management Solutions revenue increased by 24% to $8,230.7 million for the three months ended February 28, 2026, compared to $6,658.2 million in the prior year[128] Profitability - Net income for the third quarter was $560.3 million, an 8% increase from $519.3 million in the prior year[126] - Adjusted diluted earnings per share rose by 15% to $1.71, compared to $1.49 in the prior year[125] - Operating income for the third quarter was $792.0 million, a 14% increase from $691.8 million in the prior year[126] - Adjusted operating income increased by 22% to $863.2 million for the third quarter and by 19% to $2,138.9 million for the nine months[138] Expenses and Costs - Total expenses increased by 24% to $1,016.9 million for the third quarter and by 27% to $3,000.7 million for the nine months, primarily due to compensation-related expenses and acquisition-related costs[132] - Interest expense rose by $45.5 million to $68.1 million for the third quarter, primarily due to incremental debt from the acquisition of Paycor[136] Taxation - The effective income tax rate for the third quarter was 24.2%, slightly down from 24.3% in the prior year[126] - The effective income tax rate was 24.2% for the third quarter and 23.7% for the nine months, slightly lower than the previous year's rates[137] Cash Flow and Liquidity - For the nine months ended February 28, 2026, net cash provided by operating activities was $1,975.8 million, an increase of $418.7 million compared to $1,557.1 million for the same period in 2025[159] - The company had $2.0 billion of unused capacity under its unsecured credit facilities as of February 28, 2026, indicating strong liquidity[141] - The company reported net cash used in investing activities of $925.0 million for the nine months ended February 28, 2026, an increase of $643.3 million compared to $281.7 million in 2025[159] Investments and Securities - Net unrealized gains on available for sale securities improved to $7.2 million as of February 28, 2026, compared to a loss of $53.6 million in the prior year[129] - The fair value of AFS securities was $4.5 billion as of February 28, 2026, with a weighted-average yield-to-maturity of 3.6%[173] - The company has $1.6 billion of AFS securities with fair values below amortized cost, but believes principal and interest will be collected as per contractual terms[175] Shareholder Returns - Dividends paid to stockholders increased by 10% to $388.0 million for the third quarter[125] - Total cash dividends per common share increased to $3.24 for the nine months ended February 28, 2026, compared to $2.94 for the same period in 2025[159] - Cash used to repurchase 2.9 million shares of common stock at a weighted average price of $125.16 per share during the nine months[163] Acquisitions - The acquisition of Paycor contributed approximately 19% to Management Solutions revenue for the third quarter[127] - The company incurred $13.2 million in acquisition-related costs for the three and nine months ended February 28, 2025, primarily related to the Paycor acquisition[139] Interest Rates and Financial Management - The average interest rate earned on combined funds held for clients and corporate cash equivalents was 3.6%, slightly down from 3.7% in the prior year[165] - A 25-basis-point change in taxable interest rates would affect earnings by approximately $5.0 million to $5.5 million after taxes over a twelve-month period[169] - The company executed interest rate swaption contracts with an aggregate notional amount of $3.0 billion to manage exposure to interest rate fluctuations related to the acquisition financing[152] Client Funds and Obligations - Average investment balances for funds held for clients increased by 26% to $6,464.8 million for the three months ended February 28, 2026[128] - Client fund obligations liability will vary based on the timing of cash collections and remittances, impacting financing activities[160]

Economic Factors - The NIS depreciated by 9.7% against the U.S. dollar in 2023 and 0.4% in 2024, but appreciated by 6.7% in 2025, impacting the dollar value of NIS-denominated expenses[91] - Annual inflation rates in Israel were 3.0%, 3.2%, and 2.6% for the years 2023, 2024, and 2025, respectively[91] - Israel's credit rating was downgraded by Moody's from A1 to Baa1 and S&P Global lowered its long-term rating from A+ to A due to ongoing conflicts, with a negative outlook[142] - The statutory corporate tax rate for Israeli companies is 23% as of January 1, 2018, which could increase costs if tax benefits are reduced or eliminated[147] Management and Personnel - Significant changes in senior management occurred in 2024 and 2025, including the elimination of key positions, which may adversely affect the company's performance[93] - The company faces challenges in attracting and retaining qualified personnel due to competition and recent geopolitical events affecting the workforce in Israel[94] Legal and Compliance Risks - The company is currently subject to securities class action litigation, which may significantly impact its financial condition and profitability[107] - The company is subject to tax audits and potential liabilities in multiple jurisdictions, which could adversely affect its financial results[102] - The company may face claims of intellectual property infringement, which could result in costly litigation and adversely affect its business operations[114] - The company faces challenges in enforcing U.S. court judgments in Israel, which may complicate legal claims under U.S. securities laws[155] - The company must comply with the Sarbanes-Oxley Act, including certifying financial information and providing an annual management report on internal controls[133] Intellectual Property - The company relies on trade secret rights, copyrights, trademarks, and other rights to protect its proprietary intellectual property and technology[111] - The company may not be able to effectively enforce its issued patents or other intellectual property rights, which could harm its competitive position[109] - As of December 31, 2025, the company owned 60 issued patents in the United States and 42 patents issued in non-U.S. jurisdictions, along with 27 provisional or pending U.S. patent applications[110] Financial Performance and Shareholder Matters - The market price of the company's ordinary shares has been volatile, influenced by various factors including financial performance and market conditions[119] - The company has never declared or paid cash dividends on its share capital and does not anticipate doing so in the foreseeable future[121] - The company has repurchased 1,369,643 ordinary shares with an aggregate value of $19.4 million under its new share repurchase program approved in November 2025, which authorizes repurchases of up to $100 million[122] - The company’s share repurchase programs may reduce the public float of shares available for trading and could cause volatility in the price of its ordinary shares[123] - Future sales of ordinary shares by the company or its shareholders could negatively impact the market price of its shares[128] - The company has issued 3,401,028 ordinary shares underlying warrants to Amazon, with registration rights for these shares[130] - As of December 31, 2025, there are 2,496,039 ordinary shares issuable under currently vested and exercisable share options and unvested restricted share units[131] Operational Risks - The company has a significant international presence and plans to expand operations, which exposes it to risks such as contract enforcement difficulties and fluctuating exchange rates[96] - The company has acquired businesses and may pursue further acquisitions, which could disrupt operations and dilute shareholder value if not managed effectively[101] - The company has faced challenges related to unauthorized access and data breaches, which could impact customer trust and financial performance[106] - Political, economic, and military instability in Israel may adversely affect the company's operations, as its headquarters and significant operations are located there[140] - The company has not experienced significant supply chain disruptions or material adverse effects from military reserve duty call-ups during the conflicts[143] - The company has implemented business continuity plans to mitigate risks related to shipping and delivery disruptions caused by military conflicts, including increasing inventory levels in localized regions[146] Government Regulations - The company is subject to restrictions under the Innovation Law, which limits the transfer of know-how and manufacturing outside of Israel without prior approval[149] - The company is subject to local manufacturing obligations for products developed with Innovation Authority funding, which may limit operational flexibility[151] - Israeli corporate law imposes strict regulations on mergers and acquisitions, requiring significant shareholder approval and potentially delaying favorable transactions[152] - Shareholder rights and responsibilities are governed by Israeli law, which differs materially from U.S. corporate governance standards[156] - The company follows Israeli corporate governance practices, which may provide less protection to investors compared to U.S. domestic issuers under Nasdaq rules[124] - The company is exempt from U.S. proxy rules and certain requirements under the Exchange Act, potentially increasing compliance costs if its foreign private issuer status changes[125] - The SEC is considering revisions to the foreign private issuer definition, which could impose more stringent requirements on the company if it fails to meet new conditions[127] Research and Development - The company received grants from the Israeli Innovation Authority for R&D activities, covering up to 55% of expenses, amounting to NIS 4 million (approximately $1.2 million) in 2025[148]